We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
RBCC Explores New Cures for Cancer, Brain Injuries & Headaches
News

RBCC Explores New Cures for Cancer, Brain Injuries & Headaches

RBCC Explores New Cures for Cancer, Brain Injuries & Headaches
News

RBCC Explores New Cures for Cancer, Brain Injuries & Headaches

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RBCC Explores New Cures for Cancer, Brain Injuries & Headaches"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cutting-edge stem cell research is producing new breakthroughs that could potentially revolutionize the treatment of currently incurable diseases from cancer to brain injuries to headaches.

As the world’s population ages and the economic might of emerging countries such as China and India blossoms, the market is increasing daily for new and effective cures to old ailments. RBCC plans to capitalize on recent growth in the biosciences sector by commercializing advanced-stage research with the potential to produce new treatments.

RBCC is aiming high. The company’s current target, n3D Biosciences, has developed a breakthrough cell-culturing system that allows scientists to grow 3D stem cells that behave much more similarly to cells found in the body. This product may directly assist with advanced discoveries to find cures for common injuries and diseases.

With the help of its new allies in BioHouston, RBCC plans to identify new targets on the cutting-edge of biotechnology for acquisition and joint venture.

Advertisement